---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-030726"
form_type: "8-K"
ticker: "APGE"
cik: "0001974640"
company_name: "Apogee Therapeutics, Inc."
filed_at: "2024-03-05T23:59:59+00:00"
generated_at: "2026-06-05T04:14:58.129960+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Apogee reports positive Phase 1 data for APG777 with ~75-day half-life; FY2023 net loss $84M

## Summary
- APG777 Phase 1 interim data: half-life ~75 days, deep pSTAT6 and TARC suppression for ~3 months, well tolerated.
- Phase 2 in moderate-to-severe AD planned for 1H 2024; induction designed to exceed lebrikizumab exposures by 30-40%.
- Cash $395.5M at Dec 31, 2023; expected runway into Q4 2026.
- FY 2023 net loss $84.0M vs $39.8M from inception (Feb 2022) to Dec 2022; R&D expenses $68.4M.
- APG808 (anti-IL-4Rα) Phase 1 trial starting ahead of schedule; Phase 2 in COPD expected 2025.

## SEC filing metadata
- accession: 0001104659-24-030726
- form_type: 8-K
- ticker: APGE
- cik: 0001974640
- company_name: Apogee Therapeutics, Inc.
- filed_at: 2024-03-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1974640/000110465924030726/0001104659-24-030726-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1974640/000110465924030726/tm247826d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-030726
- JSON: https://secwatch.observer/filing/0001104659-24-030726.json
- Plain text: https://secwatch.observer/filing/0001104659-24-030726.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.